Testosterone

Testosterone is the starting compound for every cycle because it is the only anabolic drug whose side effect set is fully transparent and well-understood. Estrogen rises; you see it in water retention and blood pressure. Hematocrit climbs; it appears on a CBC. Libido is the best real-time gauge of whether the hormone picture is balanced. Adding more exotic compounds before mastering testosterone means attributing outcomes to the wrong variable every time something goes wrong.

At 500mg/week for 12–16 weeks with proper diet and training, a natural athlete can add 10–20 lbs of retained lean tissue, representing 2–4 years of normal progress. The compounds that experienced users eventually layer in are optimizations on top of a base that testosterone already provides effectively.

Administration: Injectable compound. Most users split into 2 injections per week to keep blood levels steadier and side effects easier to read.

Ester handling: Available as Enanthate, Cypionate, Propionate, Acetate, Decanoate, Undecanoate. Short esters usually need more frequent injections, while longer esters trade flexibility for convenience.

Cycle context: This is the usual base compound. If estrogen rises, adjust based on symptoms and labs instead of reflexively adding high-dose AI.

Stop or reduce if: blood pressure climbs, sleep degrades, libido crashes, or labs move sharply in the wrong direction.

With Enanthate or Cypionate at twice-weekly injections, blood levels reach near-steady-state by day 18–21. Weeks 1–3 typically feel mild. Scale weight moves from glycogen supercompensation and early nitrogen retention, not new tissue. Interpreting week-2 scale movement as a measure of how well the cycle is working leads to bad decisions.

Weeks 4–8: operating at full steady-state. Recovery between sessions improves. Training volume typically increases with it. The scale and the mirror start reflecting actual progress rather than just water and glycogen.

Weeks 8–16: tissue accrual is the primary variable. Diet and training compliance determine the outcome more than dose adjustment at this stage. This is where consistent execution matters more than pharmacology.

After the last injection, active levels drop meaningfully by day 14–18 with enanthate or cypionate. LH and FSH can begin responding when exogenous testosterone falls below a threshold, typically in the physiologically low range. PCT drugs (SERMs) should start when levels are in that range, which for most long-ester cycles means 14–18 days after the last injection.

Testosterone works through three pathways simultaneously. It activates androgen receptors directly. It aromatizes to estradiol, which is required for bone density, cardiovascular health, joint lubrication, mood stability, and sexual function. It converts via 5AR to DHT, which drives androgenic effects at hair, skin, and prostate tissue. Managing the balance between these pathways is the actual skill in using testosterone effectively, not just keeping estrogen “in range.”

The aromatization rate is roughly 0.2–0.3% of circulating testosterone per day, concentrated in adipose tissue. This is not fixed. Aromatase activity increases with higher testosterone substrate, higher body fat percentage, and age. A lean user at 200mg/week may have estradiol of 30–50 pg/mL. The same user at 500mg/week will typically see estradiol at 70–120 pg/mL or higher. The relationship is roughly dose-proportional within the range most users operate in, though it flattens somewhat at very high doses as aromatase enzyme begins to saturate.

Estrogen is not the enemy. Estradiol amplifies muscle protein synthesis, supports bone density, improves insulin sensitivity, contributes to cardiovascular protection, and is the primary driver of libido and mood in men on cycle. Users who suppress estradiol aggressively in pursuit of a “dry” look typically feel worse, recover worse, and often find joint pain worsening as synovial fluid depends partly on estrogen signaling. The target is not zero estrogen. It is a stable, mid-range estradiol that balances the beneficial effects against water retention and breast tissue sensitivity.

Hematocrit rises on testosterone via erythropoietin stimulation. This is dose-dependent and cumulative over cycle length. A user at 500mg/week for 16 weeks commonly sees hematocrit 4–7 percentage points above baseline. Above 52–54%, blood viscosity increases, blood pressure rises, and cardiovascular strain is measurable. Blood donation at the midpoint of a long cycle is standard practice for managing this, not optional. Starting a cycle with already-elevated hematocrit from a prior run is a genuine cardiovascular risk.

Ester selection in practice: Enanthate and Cypionate are clinically equivalent. The “cypionate holds more water” belief is incorrect. Both esters cleave to the same free testosterone. The pharmacokinetically relevant difference is half-life: enanthate is ~7 days, cypionate ~8 days. Neither matters for most protocols. Propionate has a 2–3 day half-life and produces higher peaks and troughs between injections at the same weekly dose, which some users find increases estrogen variability. For stable blood levels with twice-weekly injections, enanthate or cypionate is standard.

Front-loading: Injecting 1.5–2× the normal dose on day 1 of a long-ester cycle brings blood levels to near-steady-state in 1–2 weeks instead of 3–4 weeks. For a 16-week cycle this is meaningful: the user gains 2 full productive weeks. Front-loading introduces a brief period of elevated estrogen and should be paired with AI monitoring.

Dose ranges and what they mean:
200–300mg/week produces supraphysiological levels with modest side effects. Estrogen management is often unnecessary or minimal. Strength and recovery improve noticeably but the anabolic ceiling is limited.
400–600mg/week is the most common cycle range. Clear anabolic output, visible body composition changes over 12–16 weeks, and estrogen management becoming necessary for most users by weeks 4–6.
700mg+/week: anabolic returns per added milligram diminish while side effect accumulation does not. For most users at accessible stages of development, 600mg produces nearly the same result as 800mg with substantially less management burden.

These ranges assume lean, healthy baseline. Higher body fat, older age, or pre-existing elevated hematocrit all shift the risk picture upward.

Adding an aromatase inhibitor to fix what is a dose or injection-spacing problem. Estradiol at week 3 of a cycle is still responding to rising blood levels and may not represent the stabilized level. Drawing labs and interpreting them against symptoms gives an actual picture. Reflexive AI use before labs means guessing.

Reading early scale movement as the actual result of the cycle. The first 3–4 weeks of water weight gain on testosterone often clears post-cycle, revealing the actual lean tissue underneath, which is usually more than expected.

Running the first cycle with multiple compounds. Testosterone plus two other drugs on a first cycle eliminates the ability to attribute any result, positive or negative, to a specific cause. That information is worth more than the marginal extra result from the second and third compounds.

Cutting the cycle short because week 4 felt underwhelming. Week 4 is the beginning of actual steady-state pharmacology. Cutting off at 8 weeks means leaving the most productive period of a typical cycle on the table.

Every other compound is evaluated relative to testosterone. Nandrolone and Primo provide more anabolic signal per unit of androgenic and estrogenic exposure. Trenbolone provides recomp effects and dramatic strength with no estrogen but at a significant quality-of-life cost. Masteron hardens the physique and reduces estrogen when body fat is low. Equipoise adds work capacity and appetite stimulation with less estrogen than the equivalent testosterone dose.

None of these are replacements for testosterone. They are additions to or modifications of the base testosterone architecture, and the base still runs beneath all of them.